NASDAQ:AVROAvrobio Stock Price, Forecast & News

Avrobio's stock was trading at $18.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 3.4% and is now trading at $17.41. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Avrobio.

Avrobio Inc (NASDAQ:AVRO) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.11. View Avrobio's earnings history.

7 analysts have issued 12 month target prices for Avrobio's shares. Their forecasts range from $13.00 to $43.00. On average, they expect Avrobio's share price to reach $33.60 in the next twelve months. This suggests a possible upside of 93.0% from the stock's current price. View analysts' price targets for Avrobio.

Press coverage about AVRO stock has trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avrobio earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Avrobio.

Avrobio saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,960,000 shares, an increase of 13.3% from the June 15th total of 1,730,000 shares. Based on an average daily trading volume, of 341,000 shares, the short-interest ratio is presently 5.7 days. Currently, 6.7% of the shares of the stock are sold short. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Twist Bioscience (TWST), Immunovant (IMVT), Editas Medicine (EDIT), Alector (ALEC), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Bill.com (RVMD), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Mesoblast (MESO), Regenxbio (RGNX), Legend Biotech (PCVX), Nantkwest (NK) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Zynerba Pharmaceuticals (ZYNE).

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $17.41.

Avrobio has a market capitalization of $627.28 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

The official website for Avrobio is www.avrobio.com.

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]